4/23
08:09 am
mltx
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
Medium
Report
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
4/11
08:06 am
mltx
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
Low
Report
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
4/9
08:09 am
mltx
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $66.00 price target on the stock.
Low
Report
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $66.00 price target on the stock.
4/9
05:56 am
mltx
Rating for MLTX
Low
Report
Rating for MLTX
4/9
05:56 am
mltx
Rating for MLTX
Low
Report
Rating for MLTX
4/2
07:04 am
mltx
Rating for MLTX
Low
Report
Rating for MLTX
4/2
07:04 am
mltx
Rating for MLTX
Low
Report
Rating for MLTX
4/2
07:04 am
mltx
Rating for MLTX
Low
Report
Rating for MLTX
3/18
03:15 pm
mltx
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $92.00 price target on the stock.
Low
Report
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $92.00 price target on the stock.
3/18
03:15 pm
mltx
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $92.00 price target on the stock.
Low
Report
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $92.00 price target on the stock.
3/13
09:25 am
mltx
Rating for MLTX
Low
Report
Rating for MLTX
3/13
09:25 am
mltx
Rating for MLTX
Low
Report
Rating for MLTX
3/11
08:46 am
mltx
Rating for MLTX
Medium
Report
Rating for MLTX
3/11
08:46 am
mltx
Rating for MLTX
Medium
Report
Rating for MLTX
3/11
06:44 am
mltx
Rating for MLTX
Medium
Report
Rating for MLTX
3/11
06:44 am
mltx
Rating for MLTX
Medium
Report
Rating for MLTX
3/4
08:06 am
mltx
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
Medium
Report
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
3/1
09:03 am
mltx
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $92.00 price target on the stock.
Low
Report
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $92.00 price target on the stock.
3/1
09:03 am
mltx
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $92.00 price target on the stock.
Low
Report
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $92.00 price target on the stock.
3/1
08:37 am
mltx
Rating for MLTX
Medium
Report
Rating for MLTX
3/1
08:37 am
mltx
Rating for MLTX
Medium
Report
Rating for MLTX
3/1
08:15 am
mltx
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $66.00 price target on the stock.
Low
Report
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $66.00 price target on the stock.
3/1
05:27 am
mltx
Rating for MLTX
Low
Report
Rating for MLTX
3/1
05:27 am
mltx
Rating for MLTX
Low
Report
Rating for MLTX
2/26
05:39 pm
mltx
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "outperform" rating re-affirmed by analysts at William Blair. They now have a $92.00 price target on the stock.
Medium
Report
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "outperform" rating re-affirmed by analysts at William Blair. They now have a $92.00 price target on the stock.